Develops first-in-class covalent protein therapeutics using a proprietary synthetic biology platform that incorporates unnatural amino acids to create irreversibly binding "War-Lock" biologics. This approach improves target modulation, reduces off-target effects, and enables sustained therapeutic efficacy with minimal systemic exposure, addressing limitations of traditional protein drugs in treating cancer and other serious diseases.
Funding
$161M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
JPFounders
Product
Problem
Traditional protein therapeutics often bind reversibly to their targets, necessitating high or continuous dosing to maintain efficacy, which can lead to off-target effects and toxicity due to sustained exposure to healthy tissue. Engineering protein drugs for specific delivery to diseased areas remains a challenge, limiting their therapeutic window.
Solution
Enlaza Therapeutics is developing a new class of covalent biologics using its War-Lock™ platform to create highly selective biologic drugs engineered for irreversible binding to disease-related targets. The platform incorporates unnatural amino acids into protein drugs, enabling covalent bond formation between the drug and its target. This approach allows for sustained target occupancy and prolonged biologic effect with minimal systemic exposure, improving the separation of efficacy from off-target effects. Enlaza's technology is applicable across various protein drug formats and can be readily introduced to create optimized War-Locks for specific disease targets.
Target Audience
Enlaza's primary target audience includes researchers and clinicians focused on developing treatments for cancer and other serious diseases, particularly those seeking to overcome the limitations of traditional protein therapeutics.
Features
- War-Lock™ technology enables the generation of covalent-acting biologics with improved efficacy and safety profiles.
- Incorporation of proprietary unnatural amino acids with expanded chemical function into protein drugs.
- Target-specific activation of chemistry, rapidly forming a covalent bond between the drug and the target upon engagement.
- Rapid distribution and irreversible locking to disease-relevant targets, achieving high exposure in diseased tissues.
- Rapid clearance of unbound drug, minimizing exposure to healthy tissues.